Pyrazinamide and Pyrazinoic Acid Derivatives Directed to Mycobacterial Enzymes Against Tuberculosis

Author(s): Michelle Fidelis Corrêa, João Paulo-dos Santos Fernandes

Journal Name: Current Protein & Peptide Science

Volume 17 , Issue 3 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Tuberculosis (TB) is an infectious diseases responsible for thousands of deaths worldwide. Due to the use of antimycobacterial drugs, TB prevalence seemed to be controlled, but with the appearance of resistant tuberculosis cases, the concern about the disease had become significant again, as well as the need for new alternatives to TB treatment. Since pyrazinamide (PZA) is part of the firstline agents in TB treatment, several derivatives of this drug were described, besides pyrazinoic acid (POA) derivatives, the active form of PZA. POA has been used mainly to design prodrugs to be activated by mycobacterial esterases, while PZA derivatives should be activated specifically by the nicotinamidase/ pyrazinamidase (PZAse), or other PZAse-independent pathways. The intention of this paper is to discuss the state of art of PZA and POA derivatives and their activity against Mycobacterium tuberculosis and other mycobacteria, besides the therapeutic potential. Focus was given in prodrugs and derivatives directed to mycobacterial enzymes involved in its activation or mechanism of action.

Keywords: Antimycobacterial agents, drug design, prodrugs, pyrazinamide, pyrazinoic acid, resistant TB.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 01 October, 2015
Page: [213 - 219]
Pages: 7
DOI: 10.2174/1389203716666151002114839
Price: $65

Article Metrics

PDF: 44
PRC: 1